Biothera Appoints CEO
This article was originally published in Scrip
Executive Summary
Biothera Pharmaceutical Inc. has appointed Barry Labinger CEO – effective Dec. 14, 2015. With nearly 30 years' experience, Labinger joins the company having most recently served as executive vice president (VP) and president, biosciences division at Emergent BioSolutions, Inc. Previously he was executive VP and chief commercial officer of Human Genome Sciences, Inc. and prior to this he was division VP of 3M Pharmaceuticals. Prior to 3M, he was senior VP and general manager of commercial operations for Immunex Corporation.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.